Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CTKB 
Cytek Biosciences Inc (CTKB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CTKB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.12
1 Year Target Price $5.12
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.77% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 530.52M USD | Price to earnings Ratio - | 1Y Target Price 5.12 |
Price to earnings Ratio - | 1Y Target Price 5.12 | ||
Volume (30-day avg) 6 | Beta 1.34 | 52 Weeks Range 2.37 - 7.63 | Updated Date 08/29/2025 |
52 Weeks Range 2.37 - 7.63 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.04 | Actual -0.04 |
Profitability
Profit Margin -3.27% | Operating Margin (TTM) -23.3% |
Management Effectiveness
Return on Assets (TTM) -3.77% | Return on Equity (TTM) -1.67% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 292180154 | Price to Sales(TTM) 2.71 |
Enterprise Value 292180154 | Price to Sales(TTM) 2.71 | ||
Enterprise Value to Revenue 1.49 | Enterprise Value to EBITDA -133.96 | Shares Outstanding 127224000 | Shares Floating 108730530 |
Shares Outstanding 127224000 | Shares Floating 108730530 | ||
Percent Insiders 9.24 | Percent Institutions 63.38 |
Upturn AI SWOT
Cytek Biosciences Inc
Company Overview
History and Background
Cytek Biosciences was founded in 2006, specializing in cell analysis solutions. It focuses on developing advanced flow cytometry instrumentation and reagents, expanding its product line through innovation and strategic partnerships. The company became publicly traded in 2021.
Core Business Areas
- Cell Analysis Instruments: Cytek designs and manufactures full spectrum flow cytometers, including Aurora and Northern Lights systems, used for cell analysis in research and clinical settings.
- Reagents and Consumables: Cytek provides a range of reagents, antibodies, and consumables optimized for use with their flow cytometry systems, enhancing the quality and reliability of experimental results.
- Services and Support: Cytek offers comprehensive services and support, including training, maintenance, and application support, to ensure customers can effectively utilize their products.
Leadership and Structure
Wenbin Jiang serves as the CEO. The company has a structured leadership team comprising executives in R&D, sales, marketing, operations, and finance. Cytek operates through various departments to efficiently manage its business.
Top Products and Market Share
Key Offerings
- Aurora Flow Cytometer: Aurora is a full spectrum flow cytometer with high resolution and sensitivity, catering to advanced research applications. Competitors include Thermo Fisher (TMO) and BD Biosciences (BDX). Market share data not publicly verifiable. High-end Research market.
- Northern Lights Flow Cytometer: Northern Lights is a more accessible flow cytometer, targeting routine cell analysis. Competitors include Beckman Coulter (DHR). Market share data not publicly verifiable. Applied clinical research and high-volume assays market.
- cFluor Reagents: A suite of reagents designed specifically for Cytek's flow cytometry platforms to maximize sensitivity and minimize spillover between fluorophores. Competitors include BioLegend and eBioscience (TMO).
Market Dynamics
Industry Overview
The flow cytometry market is driven by increasing research in immunology, oncology, and drug discovery. Advancements in technology and automation are fostering growth. The market is competitive with both large and niche players.
Positioning
Cytek is positioned as an innovator in full spectrum flow cytometry. Its competitive advantages include high-performance instruments and proprietary reagents.
Total Addressable Market (TAM)
The global flow cytometry market is projected to reach billions of USD. Cytek is positioned to expand its market share through technological innovation and market penetration. Expected TAM is around $5B in 2024 with an estimated annual growth rate of 7-9%.
Upturn SWOT Analysis
Strengths
- Innovative Full Spectrum Flow Cytometry Technology
- Strong Customer Relationships
- Proprietary Reagents Optimized for Cytek Instruments
- Expanding Global Presence
- High product performance in high plex assays.
Weaknesses
- Relatively Smaller Market Share Compared to Established Competitors
- Reliance on a Specific Niche (Full Spectrum)
- High Price Points can be a barrier
Opportunities
- Increasing Adoption of Flow Cytometry in Clinical Diagnostics
- Expanding Applications in Drug Discovery and Development
- Strategic Partnerships and Collaborations
- Penetration into Emerging Markets
- Development of new assays and applications
Threats
- Intense Competition from Established Players
- Technological Disruptions by Competitors
- Economic Downturns Affecting Research Budgets
- Regulatory Changes in Healthcare
- Supply chain disruptions for critical components
Competitors and Market Share
Key Competitors
- TMO
- DHR
- BDX
Competitive Landscape
Cyteku2019s advantages lie in its innovative technology and strong customer relationships. Disadvantages include smaller market share and a need to broaden its product portfolio.
Major Acquisitions
Innograte GmbH
- Year: 2023
- Acquisition Price (USD millions): 10.5
- Strategic Rationale: Expanded Cytek's automation capabilities and improved workflow solutions for flow cytometry.
Growth Trajectory and Initiatives
Historical Growth: Cytek has shown substantial growth in revenue, driven by increasing adoption of its flow cytometry solutions.
Future Projections: Analyst estimates project continued revenue growth and profitability improvements. Data to be populated based on analyst estimates.
Recent Initiatives: Recent initiatives include product development efforts, strategic collaborations, and market expansion activities.
Summary
Cytek is a promising company in the flow cytometry market, driven by its innovative full spectrum technology. While facing competition from larger, established players, its strong customer relationships and growing adoption of its products indicate a positive trajectory. Future success depends on continued innovation and effective market penetration. The company should look out for economic headwinds and supply chain issues.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
Disclaimers:
The information provided is based on available data and analysis. Market conditions and company performance are subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytek Biosciences Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2021-07-23 | President, CEO & Chairman of the Board Dr. Wenbin Jiang Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 688 | Website https://cytekbio.com |
Full time employees 688 | Website https://cytekbio.com | ||
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.